Diazepam Trial in GAD65 Associated Epilepsy

• Status: Enrolling by invitation
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether diazepam reduces the frequency of seizures in GAD65 antibody associated epilepsy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Diazepam

Criteria

Inclusion Criteria:

• High-titer serum GAD65 positivity > 20 nmol/L High-titer serum GAD65 IgG seropositivity titer >20 nmol/L and/or CSF GAD65 seropositivity titer > 0.02 nmol/L.

• Drug-resistant focal epilepsy, having failed 2 previous anti-seizure medications.

• Stable treatment for the 1 month prior to enrollment.

• Patients must be able to give informed consent or have an appropriate representative available to do.

Exclusion Criteria:

• Alternative etiology for epilepsy.

• Already on another benzodiazepine.

• On a regularly scheduled opiate.

• Co-existing antibodies associated with seizures.

• Pregnancy or breast feeding.